EUVIMEDEUVIMED entdecken
Open Access

Deubiquitinase Ubiquitin‐Specific Protease 29 Ameliorates Pathological Cardiac Hypertrophy through Inhibiting Transforming Growth Factor β‐Activated Kinase 1

Xi Jiang iD, Yan Sun, Hongjie Shi, Zhen Liu, Jianqing Zhang, Changlu Xu, Yufeng Hu iD, Tiesheng Niu iD

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.034962 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Xi Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Shengjing Hospital of China Medical University Shenyang Liaoning Province China. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Ubiquitin-Specific Proteases, MAP Kinase Kinase Kinases, Cardiomegaly. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pathological cardiac hypertrophy, characterized by the involvement of multiple regulators, ultimately leads to heart failure in the absence of effective interventions. The identification of key factors involved is crucial for exploring novel treatments for heart failure. However, the function and pathological implications of USP29 (ubiquitin‐specific protease 29) in cardiomyocytes remain unknown. Methods and Results The impacts of USP29 on pathological cardiac hypertrophy were investigated through the use of knockout/overexpression mice and overexpression/knockdown cardiomyocytes, accompanied by bioinformatic analysis and multiple molecular biological techniques to elucidate the underlying mechanisms. We observed upregulation of USP29 protein levels in both transverse aortic constriction‐induced hypertrophic hearts (upregulated by 159.8%) and phenylephrine‐induced hypertrophic cardiomyocytes (upregulated by 184.6%). Moreover, genetic knockout of USP29 in mice exacerbated transverse aortic constriction‐induced heart hypertrophy, dysfunction, and fibrosis, whereas overexpression of USP29 in cardiomyocytes using adeno‐associated virus 9 effectively attenuated the hypertrophic response. Similarly, USP29 alleviated phenylephrine‐induced hypertrophy of primary neonatal rat cardiomyocytes. Mechanistically, the cardioprotective effects mediated by USP29 were attributed to its suppression of TAK1 (transforming growth factor β‐activated kinase 1) activation. Further molecular analysis revealed that USP29 directly interacts with TAK1 through amino acids 284 to 922 of USP29 and amino acids 1 to 306 of TAK1, subsequently inhibiting TAK1 activation via K63‐linked deubiquitination, which is indispensable for regulating cardiac hypertrophy by USP29.

Conclusions

Here, we have identified USP29 as a novel negative regulator of pathological cardiac hypertrophy. Our findings suggest that targeting either USP29 or its interaction with TAK1 could represent an innovative therapeutic strategy for treating heart failure and cardiac hypertrophy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacUbiquitin-Specific ProteasesMAP Kinase Kinase KinasesCardiomegalyAnimalsDisease Models, AnimalMice, KnockoutRatsMiceMaleSignal TransductionMice, Inbred C57BLCells, CulturedRats, Sprague-DawleyMAP Kinase Kinase Kinase 7

Stichwörter der Autor:innen

TAK1USP29deubiquitinationpathological cardiac hypertrophy

Substanzen

Ubiquitin-Specific ProteasesMAP Kinase Kinase KinasesMAP Kinase Kinase Kinase 7

Autor:innen und Institutionen

  • Department of Cardiology Shengjing Hospital of China Medical University Shenyang Liaoning Province China.
  • Department of Gastroenterology Shengjing Hospital of China Medical University Shenyang China.
  • Institute of Model Animal Wuhan University Wuhan China.
  • Gannan Innovation and Translational Medicine Research Institute Ganzhou China.
  • Key Laboratory of Cardiovascular Disease Prevention and Control, Ministry of Education First Affiliated Hospital of Gannan Medical University Gannan Medical University Ganzhou China.

ORCID-Profile: Xi Jiang, Yufeng Hu, Tiesheng Niu

Zitieren

APA

Jiang, X., Sun, Y., Shi, H., Liu, Z., Zhang, J., Xu, C., Hu, Y., & Niu, T. (2025). Deubiquitinase Ubiquitin‐Specific Protease 29 Ameliorates Pathological Cardiac Hypertrophy through Inhibiting Transforming Growth Factor β‐Activated Kinase 1. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034962

Vancouver

Jiang X, Sun Y, Shi H, Liu Z, Zhang J, Xu C, et al. Deubiquitinase Ubiquitin‐Specific Protease 29 Ameliorates Pathological Cardiac Hypertrophy through Inhibiting Transforming Growth Factor β‐Activated Kinase 1. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.034962

BibTeX
@article{Jiang2025,
  author = {Jiang, Xi and Sun, Yan and Shi, Hongjie and Liu, Zhen and Zhang, Jianqing and Xu, Changlu and Hu, Yufeng and Niu, Tiesheng},
  title = {Deubiquitinase Ubiquitin‐Specific Protease 29 Ameliorates Pathological Cardiac Hypertrophy through Inhibiting Transforming Growth Factor β‐Activated Kinase 1},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.034962}
}
Kostenlos starten →